Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer

American Journal of Obstetrics and Gynecology

Volumn 204, Issue 1, 2011, Pages 26.e1-26.e7

  Baumgart, Juliane ^a   Nilsson, Kerstin ^a,b   Stavreus Evers, Anneli ^c   Kask, Kristiina ^c   Villman, Kenneth ^a   Lindman, Henrik ^c   Kallak, Theodora ^c   Sundstrm Poromaa, Inger ^c  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

aromatase inhibitors; breast cancer; tamoxifen; urogenital symptoms; vaginal atrophy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER DYSFUNCTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; COLD SWEAT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG SAFETY; DYSPAREUNIA; EARLY CANCER; FEMALE; GYNECOLOGICAL EXAMINATION; HORMONAL THERAPY; HORMONE DETERMINATION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MICTURITION DISORDER; NIGHT SWEAT; PH; POLLAKISURIA; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; STRESS INCONTINENCE; SYMPTOM; URINARY URGENCY; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINAL IRRITATION; VAGINAL PRURITUS; VASOMOTOR DISORDER;

EID: 78650689663     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.08.035     Document Type: Article

References (33)

1. W.F. Anderson, N. Chatterjee, W.B. Ershler, and O.W. Brawley Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database Breast Cancer Res Treat 76 2002 27 36
2. Early Breast Cancer Trialists' Collaboraive group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
3. N. Lin, and E.P. Winer Advances in adjuvant endocrine therapy for postmenopausal women J Clin Oncol 36 2008 798 805
4. A. Howell, J. Cuzick, M. Baum ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
5. H. Mouridsen, A. Giobbie-Hurder, and A. Goldhirsch Letrozole therapy alone or in sequence tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
6. R.S. Braithwaite, R.T. Chlebowski, J. Lau, S. George, R. Hess, and N.F. Col Meta-analysis of vascular and neoplastic events associated with tamoxifen J Gen Intern Med 18 2003 937 947
7. I. Cohen Aromatase inhibitors and the endometrium Maturitas 59 2008 285 292
8. L. Fallowfield, D. Cella, J. Cuzick, S. Francis, G. Locker, and A. Howell Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial J Clin Oncol 22 2004 4261 4271
9. D. Koeberle, and B. Thuerlimann Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98 Breast Cancer Res Treat 105 Suppl 1 2007 55 66
10. J. Suckling, A. Lethaby, and R. Kennedy Local oestrogen for vaginal atrophy in postmenopausal women Cochrane Database Syst Rev 2006 CD001500
11. S.E. Jones, J. Cantrell, and S. Vukelja Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy J Clin Oncol 25 2007 4765 4771
12. T.J. Whelan, P.E. Goss, and J.N. Ingle Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 23 2005 6931 6940
13. D. Cella, L. Fallowfield, P. Barker, J. Cuzick, G. Locker, and A. Howell Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 2006 273 284
14. L. Morales, P. Neven, and D. Timmerman Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients Anticancer Drugs 15 2004 753 760 (Pubitemid 39281298)
15. J.E. Mortimer, L. Boucher, J. Baty, D.L. Knapp, E. Ryan, and J.H. Rowland Effect of tamoxifen on sexual functioning in patients with breast cancer J Clin Oncol 17 1999 1488 1492
16. M.J. Mourits, I. Bockermann, and E.G. de Vries Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy Br J Cancer 86 2002 1546 1550
17. R. Day Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study National Surgical Adjuvant Breast and Bowel Project Ann N Y Acad Sci 949 2001 143 150
18. L. Holmberg, and H. Anderson HABITS (hormonal replacement therapy after breast canceris it safe?), a randomised comparison: trial stopped Lancet 363 2004 453 455 (Pubitemid 38210063)
19. L. Holmberg, O.E. Iversen, and C.M. Rudenstam Increased risk of recurrence after hormone replacement therapy in breast cancer survivors J Natl Cancer Inst 100 2008 475 482
20. E. Weisberg, R. Ayton, and G. Darling Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet Climacteric 8 2005 83 92
21. A. Kendall, M. Dowsett, E. Folkerd, and I. Smith Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Ann Oncol 17 2006 584 587
22. Swedish Breast Cancer Group www.swebcg.se Accessed June 2, 2010
23. L. Fallowfield, S. Leaity, A. Howell, S. Benson, and D. Cella Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B Breast Cancer Res Treat 55 1999 189 199
24. M. Harvey, B. Kristjansson, D. Griffith, and E. Versi The Incontinence Impact Questionnaire and the Urogenital Distress Inventory: a revisit of their validity in women without a urodynamic diagnosis Am J Obstet Gynecol 185 2001 25 31
25. L.J. Fallowfield, J.M. Bliss, and L.S. Porter Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer J Clin Oncol 24 2006 910 917
26. S. Chin, M. Trinkaus, and C. Simmons Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer Clin Breast Cancer 9 2009 108 117
27. R.P. Dibi, C.G. Zettler, S.A. Pessini, A.V. Ayub, S.B. de Almeida, and G.P. da Silveira Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer Menopause 16 2009 293 300
28. E. Ferrazzi, G. Cartei, R. Mattarazzo, and M. Fiorentino Oestrogen-like effect of tamoxifen on vaginal epithelium Br Med J 1 1977 1351 1352
29. F. Boccardo, A. Bruzzi, A. Rubagotti, G.U. Nicol, and R. Rosso Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients Oncology 38 1981 281 285
30. R.R. Love, D.F. Kurtycz, D.A. Dumesic, D.W. Laube, and Y. Yang The effects of tamoxifen on the vaginal epithelium in postmenopausal women J Womens Health Gend Based Med 9 2000 559 563
31. M. Friedrich, D. Mink, C. Villena-Heinsen, A. Woll-Hermann, S. Wagner, and W. Schmidt The influence of tamoxifen on the maturation index of vaginal epithelium Clin Exp Obstet Gynecol 25 1998 121 124
32. E.A. Perez Safety of aromatase inhibitors in the adjuvant setting Breast Cancer Res Treat 105 Suppl 1 2007 75 89
33. L.E. Waetjen, J.S. Brown, K. Modelska, T. Blackwell, E. Vittinghoff, and S.R. Cummings Effect of raloxifene on urinary incontinence: a randomized controlled trial Obstet Gynecol 103 2004 261 266